Evotec SE has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the foundation, amounting to $4.9 million over 25 months and $5 million over 24 months. The grant programs will expand Evotec’s pipeline of novel TB drug candidates and advance the most promising combinations toward clinical evaluation, reducing development risk and accelerating progress toward a universal, shorter, safer and simpler TB dru...